Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Immunotherapy Study for Patients With Stage IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 47
- Registration Number
- NCT02054520
- Locations
- 🇺🇸
University of Tennessee Medical Center, Knoxville, Tennessee, United States
🇺🇸University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸Oncology Specialists, Niles, Illinois, United States
Ipilimumab 12-month Intensive Pharmacovigilance Protocol
- First Posted Date
- 2014-01-31
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 6
- Registration Number
- NCT02050594
- Locations
- 🇻🇪
Local Institution, Caracas, Venezuela
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease
- Conditions
- Interventions
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 222
- Registration Number
- NCT02046733
- Locations
- 🇦🇺
Royal Hobart Hospital, Hobart, Australia
🇪🇸Hospital Universitario 12 Octubre, Madrid, Spain
🇦🇺Coffs Harbour Health Campus, Coffs Harbour, Australia
Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma
- First Posted Date
- 2014-01-10
- Last Posted Date
- 2023-01-20
- Target Recruit Count
- 17
- Registration Number
- NCT02032810
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma
- First Posted Date
- 2014-01-06
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT02027935
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy
- Conditions
- Interventions
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT02020070
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
- First Posted Date
- 2013-12-12
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- University of Louisville
- Target Recruit Count
- 27
- Registration Number
- NCT02009397
- Locations
- 🇺🇸
James Graham Brown Cancer Center, Louisville, Kentucky, United States
Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox
- First Posted Date
- 2013-12-12
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- University of Louisville
- Target Recruit Count
- 2
- Registration Number
- NCT02009384
- Locations
- 🇺🇸
James Graham Brown Cancer Center, Louisville, Kentucky, United States
Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-28
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 14
- Registration Number
- NCT01998126
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 169
- Registration Number
- NCT01950390
- Locations
- 🇺🇸
Saint Vincent Healthcare, Billings, Montana, United States
🇺🇸Montana Cancer Consortium NCORP, Billings, Montana, United States
🇺🇸Adena Regional Medical Center, Chillicothe, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.